selected publications
-
academic article
-
Aldosterone blockade added to renin-angiotensin system blockade to reduce albuminuria – A path for improved renoprotection?.
The American Journal of the Medical Sciences.
355.
2018
Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.
Journal of Diabetes and its Complications.
32.
2018
Diagnosis of diabetic kidney disease: state of the art and future perspective.
Kidney International Supplements.
8.
2018
Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study.
Endocrinology Diabetes & Metabolism.
1.
2018
Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study.
PLoS ONE.
13.
2018
Interpretation of HbA1c in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database.
Diabetic Medicine.
35.
2018
Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives.
Néphrologie & Thérapeutique.
14.
2018
SP418COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA..
Nephrology,Dialysis and Transplantation.
33.
2018
Serum uric acid and progression of diabetic nephropathy in type 1 diabetes.
Journal of Diabetes and its Complications.
32.
2018
The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial.
Diabetic Medicine.
35.
2018
Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients.
Acta Diabetologica.
55.
2018
YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology.
Kidney International.
93.
2018
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
The Lancet Diabetes & Endocrinology.
5.
2017
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Clinical Journal of the American Society of Nephrology.
12.
2017
Effect of large weight reductions on measured and estimated kidney function.
BMC Nephrology.
18.
2017
Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
Journal of Diabetes and its Complications.
31.
2017
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial.
Diabetes Obesity and Metabolism.
19.
2017
Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial..
Annals of Translational Medicine.
5.
2017
Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes.
Diabetes Care.
40.
2017
Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium–Glucose Cotransporter 2 Inhibitors—A Nationwide, Retrospective Cohort Study, 1995–2014.
Diabetes Care.
40.
2017
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
Kidney International.
91.
2017
Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
Kidney International.
92.
2017
Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
Journal of Diabetes and its Complications.
31.
2017
Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
Clinical Journal of the American Society of Nephrology.
12.
2017
Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
Nephrology,Dialysis and Transplantation.
33.
2017
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
BMJ Open.
7.
2017
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.
Cardiovascular Diabetology.
16.
2017
The effect of liraglutide on renal function: A randomized clinical trial.
Diabetes Obesity and Metabolism.
19.
2017
Toe–brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria.
Diabetologia.
60.
2017
Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes – A comparative study of two markers to identify high risk patients.
Redox Biology.
13.
2017
Variability in response to albuminuria‐lowering drugs: true or random?.
British Journal of Clinical Pharmacology.
83.
2017
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.
Diabetes Obesity and Metabolism.
18.
2016
Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial.
BMJ Open.
6.
2016
Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis..
Nephrology,Dialysis and Transplantation.
32.
2016
Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.
Journal of the Renin-Angiotensin-Aldosterone System.
17.
2016
Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.
BMJ Open.
6.
2016
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
The Lancet Diabetes & Endocrinology.
4.
2016
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Journal of Diabetes and its Complications.
30.
2016
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study..
Nephrology,Dialysis and Transplantation.
32.
2016
Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.
Journal of the American Society of Nephrology.
26.
2015
Effects of RAS inhibitors on diabetic retinopathy.
The Lancet Diabetes & Endocrinology.
3.
2015
Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
Journal of Diabetes and its Complications.
29.
2015
Improving the effectiveness of short‐term courses for multidisciplinary health care professionals.
Practical Diabetes.
32.
2015
Microalbuminuria: A parameter that has changed diabetes care.
Diabetes Research and Clinical Practice.
107.
2015
Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy.
Clinical Journal of the American Society of Nephrology.
10.
2015
The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.
Journal of Diabetes and its Complications.
29.
2015
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment.
Diabetic Medicine.
32.
2015
A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.
European Journal of Preventive Cardiology.
21.
2014
Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
Nephrology,Dialysis and Transplantation.
29.
2014
Sequential RAAS Blockade: Is It Worth the Risk?.
Advances in Chronic Kidney Disease.
21.
2014
Tissue Renin–Angiotensin Systems: A Unifying Hypothesis of Metabolic Disease.
Frontiers in Endocrinology.
5.
2014
-
dataset
-
Clinical characteristics of the study population at baseline categorized according to growth differentiation factor 15 and fibroblast growth factor 23 below or above the median..
public-library-of-science.
2018
Stepwise Cox regression analyses: Biomarkers in relation to risk of fatal and nonfatal cardiovascular events, all-cause mortality and decline in eGFR >30% in 200 patients..
public-library-of-science.
2018